Background: Antibiotics used to treat Clostridioides difficile infection (CDI) can predispose patients to recurrent CDI (rCDI). Gut microbiome restoration by fecal microbiota transplantation is recommended by multiple guidelines after ≥2 episodes of rCDI, with no guideline-recommended options to restore the microbiome earlier in the course of CDI. RBX2660 is a standardized, microbiota-based live biotherapeutic being […]

Background: Clostridioides difficile is an opportunistic pathogen that causes an estimated 500,000 infections per year in the United States. RBX2660, a standardized, microbiota-based live biotherapeutic, is being investigated as a treatment option for recurrent C. difficile infection (rCDI). RBX2660 has demonstrated consistent tolerability and efficacy in reducing rCDI across 6 clinical studies. We present a […]

Background: Clostridioides difficile infection (CDI) is the most common health care–associated infection in the United States and has serious clinical consequences with limited data on economic impact on US hospitals. The objective of this study was to quantify the cost of hospitalizations, readmissions, and expected reimbursement for each all-cause and CDI-related hospitalization during 12 months […]

Background: Clostroidiodes difficile (CD) is the most prevalent hospital-acquired infection in the United States, accounting for approximately 224,000 infections with 13,000 deaths and over 1 billion dollars spent in 2017, according to the Centers for Disease Control and Prevention (CDC). Clostroidiodes difficile accounts for 10-20% of diarrhea in the setting of recent antibiotics exposure.In St […]